Vol.

No.

May 06, 2022May 06, 2022

DOWNLOAD THE PDF

FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done

Cover Story

Conversation with The Cancer Letter

FDA’s Lola Fashoyin-Aje: It’s time to increase racial diversity in trials—here’s a draft guidance for how this can be done

By Matthew Bin Han Ong

FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.

Regulatory News

Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand

By Alice Tracey

Capitol Hill

Whither ARPA-H? What can Biden’s agency do that cancer centers can’t?

By Paul Goldberg

Guest Editorial

Let’s learn from our neighbors from the North as we get the menthol flavor out of cigarettes

By David Balis

Free In the Archives

The John Cleland photo archive

Clinical Roundup

Uterine cancer deaths are rising in the U.S.; rates highest in Black women

ACS studies find increase in use of PBT in cancer, with significant racial disparities

ACS study shows medical financial hardship increases mortality risk for cancer survivors

ACS study: AYA cancer survivors face increased cancer incidence and mortality risk

SWOG study: Patients with metastatic prostate cancer living significantly longer

ASCO guidelines describe best practices for treating CAR T-cell toxicities

GIST researchers develop deep learning model to predict adverse drug-drug interactions

Racial and ethnic disparities persist for early-stage breast cancer detection and survival

Combination therapy targeting angiogenesis drivers demonstrates durable clinical activity in platinum-resistant ovarian cancer

Drugs & Targets

Enhertu receives FDA approval for breast cancer indication

Imfinzi + chemo granted FDA Priority Review for locally advanced or metastatic biliary tract cancer

Aptose granted Fast Track Designation from FDA for HM43239 in relapsed/refractory AML patients and FLT3 Mutation

EC approves Kymriah in relapsed or refractory follicular lymphoma

EC approves Cabometyx as a second-line treatment for radioactive iodine-refractory differentiated thyroid cancer

Myriad Genetics expands partnership with Intermountain Precision Genomics, adding liquid biopsy therapy selection offering

Aadi Bioscience issues unique permanent J-code for Fyarro from CMS

NCI Trials

NCI Trials for May 2022

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 33 - September 12, 2025